Posted by Michael Wonder on 07 Sep 2020
Four new medicines accepted by SMC through an expedited approach
7 September 2020 - Medicines accepted to minimise delay in patient access following the early phase of the COVID-19 pandemic.
The SMC has accepted the following medicines:
- Pertuzumab (Perjeta) for the adjuvant treatment of early stage breast cancer
- Caplacizumab (Cablivi) for acquired thrombotic thrombocytopenic purpura
- Sodium zirconium cyclosilicate (Lokelma) for the treatment of hyperkalaemia
- Brolucizumab (Beovu) for the treatment of the ‘wet’ form of age-related macular degeneration
